Last night in the San Francisco Bay Area, I joined other BrightInsight executives at the 2022 Deloitte Technology Fast 500™ event. Now in its 28th year, the Deloitte Technology Fast 500™ provides a ranking of the fastest-growing technology, media, telecommunications, life sciences, fintech, and energy tech companies—both public and private—in North America. Technology Fast 500 award winners are selected based on percentage fiscal year revenue growth from 2018 to 2021.
Brightinsight ranked in the top 50% of the list at Number 217 with 701% revenue growth underscoring our position as the de facto digital health platform for the world’s top biopharma and medtech companies. The significant growth we achieved is attributed to our highly differentiated technology and our team’s proven ability to deliver digital solutions quickly and in a compliant manner.
Our biopharma and medtech customers trust BrightInsight to bring to market patient apps, Software as a Medical Device (SaMD), algorithms and other solutions that support the patient journey and add value to their therapies and devices.
Building on this momentum and growth, 2022 has truly been a banner year for us, with expansion across our customer and product portfolio and the launch of the BrightInsight Ecosystem, a global partner ecosystem to enable digital innovation, scale and adoption.
BrightInsight launched our Disease Management Solution for biopharma and medtech companies to enhance the patient experience and drive value for their therapies and devices, as well as a Connected Diagnostics Platform for leading in vitro diagnostics companies to transform device management from reactive to proactive. And we announced new customers including Sanofi and bioMérieux and an expanded enterprise agreement with CSL Behring to scale their rare disease digital health apps across regions and therapies.
A huge congratulations to the entire BrightInsight team on this important achievement. Our momentum continues to grow! Onward and upward!